S-1/A: Papa Medical Inc. Files S-1/A for Nasdaq IPO

Papa Medical Inc., a pioneering provider of Hemp dosing solutions, filed an S-1/A for its initial public offering of 1.25 million Class A common shares at an estimated US$4 per share, seeking Nasdaq listing.

Summary

• Papa Medical Inc. is launching an initial public offering of 1,250,000 shares of Class A common stock at an estimated price of US$4.00 per share.
• The company intends to list its Class A common stock on the Nasdaq Capital Market under the symbol PAPA, with the offering contingent upon final Nasdaq listing approval.
• Underwriters have a 45-day option to purchase up to an additional 187,500 shares of Class A common stock to cover over-allotments.
• The estimated net proceeds from the offering are approximately US$4,118,000, assuming no exercise of the over-allotment option.
• Proceeds are planned to be allocated as follows: 30% (US$1,235,400) for R&D, 30% (US$1,235,400) for plant and facilities upgrades, 25% (US$1,029,500) for sales and marketing, and 15% (US$617,700) for working capital and general corporate purposes.
• The company is an end-to-end provider of innovative Hemp dosing solutions in the US, specializing in medical atomization and nebulizing, and selling nebulizers.
• Key activities include R&D, formulation design, e-liquid production, e-liquid filling, and e-liquid co-packing services in the Hemp cannabinoid E-vapors industry.
• Primary revenue sources are Hemp cannabinoid E-vapors and consuming E-vapors, which collectively accounted for 91.5% of total revenues for the three months ended March 31, 2025, and 89.4% for the year ended December 31, 2024.
• The company utilizes proprietary technologies such as AiMesh (AI-driven atomization for precise dosing) and feelmixX (aroma molecule blending for CBD/E-vapor oil).
• Revenue increased by 107.3% to US$17.9 million for the three months ended March 31, 2025, compared to US$8.6 million for the same period in 2024.
• Net income for the three months ended March 31, 2025, increased by 152.5% to US$0.8 million, from US$0.3 million in the prior year period.
• For the full year ended December 31, 2024, total revenues increased by 49.0% to US$37.7 million from US$25.3 million in 2023.
• However, net income for the full year ended December 31, 2024, decreased by 43.1% to US$0.9 million from US$1.5 million in 2023.
• The company is classified as a 'controlled company' under Nasdaq rules because CEO Jian Hua holds 96.57% of the outstanding voting power.

Sentiment

Score: 6

Explanation: The company exhibits strong revenue growth and innovative technology in a high-growth market, positioning itself as a pioneer. However, the significant decline in full-year net income for 2024 despite revenue growth, coupled with contracting gross margins and negative operating cash flow in recent interim periods, raises concerns about profitability and cash generation efficiency. Substantial regulatory risks in the Hemp industry, high customer/supplier concentration, and extensive related-party transactions (including the CEO's controlling interest) introduce considerable uncertainty and corporate governance concerns. The IPO provides capital for growth, but the inherent risks and mixed financial performance suggest a cautious outlook.

Positives

• Strong revenue growth, with total revenues increasing by 107.3% to US$17.9 million for Q1 2025 and by 49.0% to US$37.7 million for FY 2024.
• Significant increase in net income for the most recent quarter, up 152.5% to US$0.8 million for Q1 2025.
• Positioned as a pioneering end-to-end innovative Hemp dosing solution provider in the US, with a medical atomization and nebulizing background.
• Possesses proprietary technologies like AiMesh (AI-driven precise dosing) and feelmixX (aroma molecule blending), enhancing product efficacy and user experience.
• Engages in the revolutionization of healthier nicotine ingestion experience with No Heat No Burn (NHNB) technology, which could mitigate health risks for end-users.
• Holds an Industrial Hemp Inhalable Authorization from the California Department of Public Health, Food and Drug Branch, ensuring regulatory compliance for certain products.
• Strategic growth plans include global expansion, continued R&D innovation, diversification into the medical products sector, and scaling up production capacity.
• Improved brand recognition and expanded customer base, adding 35 new clients in 2024.

Negatives

• Net income for the full year 2024 decreased by 43.1% to US$0.9 million from US$1.5 million in 2023, despite significant revenue growth, primarily due to operating expenses increasing at a faster rate than gross profit.
• Gross profit margin contracted to 22.3% for Q1 2025 from 25.1% for Q1 2024, attributed to volume-related cost increases, product mix adjustments, and strategic reductions in average selling prices for certain products.
• Operating expenses increased substantially: selling and marketing expenses rose by 72.4% in 2024, general and administrative expenses by 171.0% in 2024, and R&D expenses by 90.1% in 2024.
• Negative net cash used in operating activities for the three months ended March 31, 2025 (US$2.2 million) and March 31, 2024 (US$1.3 million), primarily driven by increases in inventories and decreases in advances from customers and amounts due to related parties.
• High customer concentration, with two customers collectively representing approximately 69.2% of total revenues for Q1 2025 and 56.7% for FY 2024.
• Significant supplier concentration, with three suppliers accounting for approximately 47.8% of total purchases for Q1 2025 and four suppliers accounting for 79.8% of accounts payable as of March 31, 2025.
• Reliance on related party transactions, including purchases and services from Shenzhen Feellife (controlled by the CEO) and a lease agreement with Cpresso, LLC (also controlled by the CEO's related party), with lease rates previously more favorable than market rates.
• Incurred an impairment loss of US$87,392 on fixed assets in 2024.
• A significant portion of cash and cash equivalents (US$1,610,438 as of March 31, 2025) held by financial institutions were uninsured by the FDIC.

Risks

• Existing laws, regulations, and policies, and the issuance of new or more stringent ones, in the E-vapors and/or Hemp cannabinoid vapor industry can materially and adversely affect business operations.
• Changes in enforcement priorities at the state level with respect to certain Hemp cannabinoids could materially and adversely affect business operations.
• Hemp cannabinoid E-vapors are subject to varying and rapidly changing regulations across US states and are prohibited in many other countries.
• The United States federal government could change the definition of Hemp to prohibit Hemp cannabinoid products generally and/or to prohibit synthetic hemp cannabinoid products, such as Delta-8 THC.
• Products could be subject to product liability legal claims as a result of adverse events or perceived health risks.
• Legal proceedings alleging violations of the Federal Paraphernalia Law or changes in its interpretation could adversely affect the business.
• CEO Jian Hua's controlling ownership (96.57% of voting power) creates a conflict of interest, as his interests may differ from other shareholders.
• Exposure to risks relating to relationships with certain related parties, including potential interruptions, failure to accommodate growing business demands, or termination of cooperation terms.
• Legislation and regulations relating to delivery, sales, and shipping restrictions of tobacco products in the United States (e.g., PACT Act, USPS/FedEx/UPS bans) may make it more difficult to sell Hemp cannabinoid E-vapors and consuming E-vapors.
• If the use of Hemp cannabinoid E-vapors and consuming E-vapors is determined or perceived to pose long-term health risks, their use may decline significantly.
• The E-vapors market may develop more slowly or differently than expected due to uncertainties in acceptance, health studies, economic conditions, and regulatory landscape.
• Intense competition from companies in the E-vapors industry as well as other sources of nicotine and Hemp.
• Risk of infringement of intellectual property by third parties or loss of intellectual property rights.
• Competition for highly skilled employees is intense, and inability to attract and retain them could adversely affect efficiency and operations.
• Internal control over financial reporting may not be effective, and deficiencies could have a material adverse effect on business and reputation.
• Nasdaq may apply additional and more stringent criteria for initial and continued listing due to the small public offering size and large insider holdings.
• As a controlled company under Nasdaq rules, investors may not have the protection of certain corporate governance requirements.
• The company will incur increased costs as a result of being a public company.
• Substantial future sales or perceived potential sales of shares in the public market could cause the price of shares to decline.
• Uncertainties in the interpretation and enforcement of PRC laws and regulations may significantly limit or completely hinder the ability to offer or continue to offer shares and cause the value of shares to decline or become worthless.
• Subject to governmental regulations, other legal obligations, and liability related to privacy, information security, and data protection (e.g., CCPA, GDPR).
• Cyber-attacks and security vulnerabilities could result in serious harm to reputation, business, and financial condition, as evidenced by a recent ransomware incident at a Representative.
• Any global systemic economic and financial crisis could negatively affect business, results of operations, and financial condition.
• Misuse or abuse of products may lead to potential adverse health effects, subjecting the company to complaints, product liability claims, and negative publicity.
• Supply chain issues, including reliance on Shenzhen Feellife, could materially impact business operations.
• Failure to maintain sufficient inventory or adequately manage inventory could lead to lost sales or higher inventory-related expenses.
• Misconduct, including illegal, fraudulent, or collusive activities, by employees, customers, suppliers, and manufacturers, may harm brand and reputation.
• Risk of FDA enforcement actions, including classification of products as unapproved drugs, warning letters, or lawsuits.
• Hemp-cannabinoid products are subject to advertising and FTC enforcement actions for unsupported health claims.
• Hemp-cannabinoid products may be impacted by future DEA enforcement of its interpretation of federal law, particularly regarding synthetically derived THCs.
• Tax authorities (IRS) may claim certain Hemp-derived cannabinoids are illegal and disallow tax deductions for related expenses under Section 280E of the U.S. Internal Revenue Code.
• Uncertainty exists regarding the enforceability of civil liabilities in PRC courts against executive officers and directors located in mainland China.
• Independent director candidate Joel Adalberto Gallo is a co-defendant in an ongoing securities class action lawsuit, though a settlement is proposed.

Future Outlook

The company plans to pursue global expansion by rapidly entering new regional markets, while fully committing to research, development, and innovation. It intends to diversify by exploring the medical products sector and enhancing production capacity through a comprehensive upgrade of its subsidiary, CANNAPRESSO LAB INC. The strategic goal is to position itself as the leading provider of the 'third way of dosing' and integrated medical and commercial Hemp vaporization solutions in the United States. The company anticipates increased selling and marketing expenses as it expands its sales force and expects R&D expenses to vary. It also projects additional expenses from operating as a public company. While current cash and operations are believed to be sufficient for the next twelve months, the company may seek additional capital through equity or debt financing for future growth and investments. No cash dividends are expected in the foreseeable future, with earnings to be reinvested in business development.

Management Comments

• "We believe our full-cycle operations and leading market position will position us to further capitalize on the growth potential of the US Hemp cannabinoid E-vapors market."
• "By leveraging our in-house innovative technology, strong manufacturing capabilities and deep-insight into end-users needs, we develop superior e-vapor products."
• "We believe the application of our feelmixX technology effectively improves users vaping experience and at the same time creates new possibilities for the innovation and development of Hemp dosing products."
• "We believe that we have the ability to evaluate and quickly respond to the market need for E-vapors and develop products for both the Hemp cannabinoid E-vapors and consuming E-vapors markets."
• "We believe that we have implemented systems of quality control that cover the key steps of supply chain management to provide high-quality products to end customers in a consistent manner."
• "We believe that this matter [Joel Adalberto Gallo lawsuit] is not expected to have a material adverse effect on our business or Mr. Gallo’s ability to serve as a director."
• "We believe that our current cash, cash to be generated from our operations and access to capital market will be sufficient to meet our working capital needs for at least the next twelve months."
• "We believe that we are well-positioned to effectively compete on the factors listed above [diversification of R&D personnel, comprehensive qualifications, diversified product layout, efficient supply chain]."

Industry Context

Papa Medical Inc. operates within the rapidly evolving US Hemp cannabinoid E-vapors and nebulizer industries. The US Hemp cannabinoid E-liquid market grew from US$879.9 million in 2020 to US$3,057.6 million in 2024 (36.5% CAGR) and is projected to reach US$8,890.5 million by 2029 (22.3% CAGR). Similarly, the US Hemp cannabinoid E-vapor market grew from US$502.8 million in 2020 to US$1,528.8 million in 2024 (32.1% CAGR), with projections to reach US$3,232.9 million by 2029 (15.0% CAGR). The broader US end-to-end Hemp dosing solution industry saw growth from US$1,728.4 million in 2020 to US$5,733.0 million in 2024 (35.0% CAGR), expected to hit US$15,154.3 million by 2029 (20.1% CAGR). The US nebulizer market also expanded from US$1.7 billion in 2020 to US$2.6 billion in 2024 (12.1% CAGR), with an anticipated 11.7% CAGR from 2025-2029. Key market drivers include broadening applications beyond recreation (e.g., medical uses for pain relief and anxiety), increasing regulatory clarity (like the 2018 Farm Bill), strategic vertical integration, and continuous product innovation (e.g., terpenes, NHNB technology). The industry is fragmented with over 400 participants, but fewer than 50 are end-to-end solution providers. The company highlights its first-mover advantage and unique position as one of the few providers with a medical atomization/nebulizing background and engagement in NHNB technology.

Comparison to Industry Standards

• The company claims to be the 'first end-to-end innovative Hemp dosing solution provider in the US that possesses the medical atomization or nebulizing background and sells nebulizers,' suggesting a unique market position compared to traditional vaping corporations and Hemp dosing product brand operators.
• The company states it is one of 'few end-to-end innovative Hemp dosing solution provider in the US that engages in the revolutionization of healthier nicotine ingestion experience with NHNB,' indicating a competitive edge in advanced, health-conscious vaping technology.
• The company asserts that its 'full-cycle operations and leading market position enables us to stand out in the Hemp cannabinoid E-vapors and consuming E-vapors markets,' implying superior operational control and market penetration compared to competitors.
• The company's supply prices from related party Shenzhen Feellife are stated to be 'in line with market rates of other non-related parties,' suggesting competitive sourcing costs.
• Lease rates paid to related party Cpresso, LLC were 'more favorable than the market rates of other non-related parties' but are expected to adjust to market rates from January 1, 2025, indicating a move towards industry standard pricing for this related-party transaction.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal or administrative proceedings are currently pending against Papa Medical Inc. or its subsidiaries as of the date of the prospectus.
• Joel Adalberto Gallo, an independent director candidate, is a co-defendant in a securities class action lawsuit, Daniel Perrier v. Hywin Holdings Ltd., et al., filed in March 2024 in the Supreme Court of the State of New York for the County of New York.
• The lawsuit against Mr. Gallo alleges violations of the Securities Act of 1933 related to alleged misstatements or omissions in the offering documents of Hywin Holdings Ltd.'s 2021 IPO, where he served as an independent director.
• A settlement for the class action lawsuit is proposed, and Mr. Gallo has denied any wrongdoing, with no finding of liability against him.
• The company believes this matter is not expected to have a material adverse effect on its business or Mr. Gallo's ability to serve as a director.

Related Party Transactions

• The company has significant amounts due to Shenzhen Feellife, an affiliate directly controlled by CEO Jian Hua, totaling US$4,341,359 as of March 31, 2025, and US$4,826,976 as of December 31, 2024.
• Purchases from Shenzhen Feellife amounted to US$680,923 for Q1 2025, US$1,028,969 for Q1 2024, US$4,186,353 for FY 2024, and US$2,380,350 for FY 2023.
• Service expenses paid to Shenzhen Feellife for business process outsourcing (including R&D, marketing, financial expertise, production management) were US$673,237 for Q1 2025, US$422,936 for Q1 2024, US$2,240,245 for FY 2024, and US$1,624,431 for FY 2023.
• The company entered into a lease agreement with Cpresso, LLC, a related party controlled by Shenzhen LFS (which is controlled by CEO Jian Hua), for a real estate property in California.
• Rental expenses paid to Cpresso, LLC were US$113,250 for Q1 2025, US$24,000 for Q1 2024, and US$96,000 for both FY 2024 and FY 2023.
• The lease rates paid to Cpresso, LLC were 'more favorable than the market rates of other non-related parties' but are expected to be adjusted to market rates from January 1, 2025.
• A Debit Waiver Agreement dated April 1, 2024, centralized net balances from twelve other related parties to Shenzhen Feellife for management and settlement.
• The company relies on Shenzhen Feellife for services and has not considered other third-party suppliers, citing manageable risk due to common control by the CEO.

Stakeholder Impact

• Shareholders: Will experience immediate and substantial dilution upon IPO. Their ability to influence corporate matters will be limited due to the dual-class share structure and the CEO's controlling voting power. Returns will primarily depend on share price appreciation as no dividends are expected in the foreseeable future. They are exposed to significant regulatory, market, and related-party risks.
• Employees: The company's growth strategies may lead to expansion of the sales force and R&D personnel, potentially creating new opportunities. However, competition for skilled employees is intense. Operating as a public company will increase administrative burdens and costs.
• Customers: May benefit from continued product innovation (AiMesh, feelmixX, NHNB technology) and diversified product offerings. However, potential regulatory changes or negative health perceptions could impact product availability or consumer demand. High customer concentration means the loss of a major customer could significantly impact the company.
• Suppliers: The company has high supplier concentration, including significant reliance on related party Shenzhen Feellife. Any interruption or failure by these key suppliers could adversely affect production and operations.
• Creditors: The company's financial health and ability to generate sufficient cash flow will impact its ability to meet financial obligations. Future capital raises (equity or debt) could alter the company's capital structure and risk profile for creditors.

Next Steps

• Obtain final approval for listing Class A common stock on the Nasdaq Capital Market.
• Complete the initial public offering of 1,250,000 shares of Class A common stock.
• Proceed with global expansion plans to enter new regional markets.
• Continue to commit to research, development, and innovation for new and existing products.
• Explore and expand into the medical products sector.
• Enhance production capacity and diversify product offerings through a comprehensive upgrade of CANNAPRESSO LAB INC.
• Work towards positioning the company as the leading provider of the 'third way of dosing' and integrated medical and commercial Hemp vaporization solutions in the United States.
• File the Final Prospectus and other required reports with the SEC.
• Monitor and adapt to evolving regulatory landscapes, particularly concerning Hemp and E-vapor products.
• Potentially seek additional equity or debt financing in the future to support growth strategies or address cash requirements.

Key Dates

Recommendation

Papa Medical Inc. operates in a high-growth, innovative segment of the E-vapors and nebulizer markets, demonstrating strong revenue expansion and proprietary technology. The company's strategic focus on R&D and global expansion is positive. However, the significant decline in full-year 2024 net income despite revenue growth, coupled with contracting gross margins and negative operating cash flow in recent interim periods, raises concerns about profitability and cash generation efficiency. The substantial regulatory risks in the Hemp industry, high customer/supplier concentration, and extensive related-party transactions (especially the CEO's controlling interest and favorable related-party lease terms) introduce considerable uncertainty and corporate governance concerns. While the IPO provides capital for growth, the inherent risks and mixed financial performance suggest a 'Hold' recommendation for seasoned investors, advising caution until the company demonstrates sustained profitability, improved cash flow from operations, and clearer navigation of its complex regulatory and related-party landscape.

Keywords

Hemp dosing, E-vapors, nebulizers, medical devices, CBD, Delta-8 THC, AiMesh technology, feelmixX technology, IPO, Nasdaq listing, ODM, Cannapresso, No Heat No Burn, vapor products, cannabis industry, regulatory compliance, product liability, supply chain management, corporate governance, financial reporting